Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review

Rezapoor, Aziz; Alidoost, Saeide; Asgharzadeh, Asra; Farhadi, Zeynab; Khodadadi, Najme; Bakhsh, Roghayeh Mohammadi; Sepehrian, Razieh; Salemi, Morteza; Mirghaed, Masood Taheri; Behzadifar, Masoud; Sohrabi, Rahim

doi:10.47176/mjiri.34.41

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With rapid economic development and urbanization, the burden of gout has increased in many parts of the world, and the burden on the health system has also gradually increased, 6 becoming an increasingly serious public health problem. The overall planning of the health system requires careful assessment of the epidemiology of gout.…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions

Han,

Chen,

Qiu

et al. 2024

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Background: Understanding the global burden of gout in the past and future can provide important references for optimizing prevention and control strategies in healthcare systems. Objectives: This study aimed to report variations in the global disease burden and risk factors of gout in 204 countries and territories from 1990 to 2019. Design: We conducted a retrospective analysis of gout based on the latest Global Burden of Disease (GBD) 2019 database. Methods: We collected data on the prevalence, incidence, and disability-adjusted life years (DALYs) of gout from 1990 to 2019. The data were then stratified by age, sex, and economic development level. Decomposition analysis, frontier analysis, and prediction models were used to analyze the changes and influencing factors influencing each indicator. Results: Globally, there were 53,871,846.4 [95% uncertainty interval (UI): 43,383,204.6–66,342,327.3] prevalent cases, 92,228,86.8 (95% UI: 7419,132.1–11,521,165) incident cases, and 1673,973.4 (95% UI: 1,068,061.1–2,393,469.2) cases of DALYs of gout in 2019, more than double those in 1990. Moreover, the pace of increase in the age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age-standardized DALY rate (ASDR) accelerated during 1990–2019, with estimated annual percentage changes (EAPC) of 0.94 [95% confidence interval (CI): 0.85–1.03], 0.77 (95% CI: 0.69–0.84), and 0.93 (95% CI: 0.84–1.02), respectively, especially among men. The disease burden of gout has increased in all the other 20 GBD regions in the past 30 years, except Western Sub-Saharan Africa. The highest risk of high body mass index (BMI) and kidney dysfunction was in high-income countries such as North America and East Asia. The global prevalence rate, incidence rate, and DALYs rate of gout in 2030 will reach 599.86, 102.96 per 100,000 population, and 20.26 per 100,000 population, respectively, roughly the same as in 2019. Conclusion: With the development of society, the disease burden of gout will become increasingly severe. It is very important to study the accurate epidemiological data on gout for clinical diagnosis and treatment and health policy.

show abstract

Section: Introductionmentioning

confidence: 99%

Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions

Han,

Chen,

Qiu

et al. 2024

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…[4][5][6] Moreover, high SUA levels can cause significant economic losses to patients, including direct (eg medical consultation fees) and indirect (eg loss of productivity) costs. [7][8][9] However, there are relatively few published studies on the association between SUA levels in gout patients and examination fees and complications. Therefore, this study aimed to analyze the relationship between different SUA levels of patients with gout and their examination fees and complications using a cross-sectional study to provide a relevant basis for the optimal diagnosis, treatment, and management of patients with gout at different SUA levels and to maximize clinical and economic benefits for patients.…”

Section: Introductionmentioning

confidence: 99%

“…It has been demonstrated that gout and hyperuricemia are related to various complications, such as hypertension, coronary heart disease, myocardial infarction, kidney diseases, and liver diseases 4–6 . Moreover, high SUA levels can cause significant economic losses to patients, including direct (eg medical consultation fees) and indirect (eg loss of productivity) costs 7–9 . However, there are relatively few published studies on the association between SUA levels in gout patients and examination fees and complications.…”

Section: Introductionmentioning

confidence: 99%

Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross‐sectional analysis

et al. 2023

View full text Add to dashboard Cite

Objective Correlation influence factor analysis of gout patients' serum uric acid (SUA) levels, their examination fees, and various complications were explored. Methods From January 2017 to December 2021, 17 666 patients with gout were obtained. Conduct quartile grouping according to gout patients' SUA levels was used to compare the differences between groups in terms of examination fees and complications. Kernel density estimation method was adopted to analyze the data distribution, Spearman and Mantel‐Haenszel χ2 tests were used to analyze the correlation between SUA levels and examination fees and complications. Binary logistic regression analysis was used to analyze the correlation influence factor between SUA levels and complications. Results Of the 17 666 gout cases, 85.46% were male. Among them, 7637 (43.23%) were inpatients and 10 029 (56.77%) were outpatients. Compared with outpatients, age, SUA levels, and examination fees were significantly higher, and there were more complications among inpatients (P < 0.05). Correlation analysis revealed that outpatients and SUA levels of patients with gout were positively correlated with examination fees, cardiovascular diseases, pulmonary diseases, liver diseases, and kidney diseases (P < 0.01). Binary logistic regression analysis showed that SUA level is an independent influence factor for cardiovascular diseases, pulmonary diseases, liver diseases, and kidney diseases (odds ratio [95% confidence interval]: 1.002 [1.002‐1.002], 1.001 [1.000‐1.001], 1.003 [1.002‐1.003], and 1.001 [1.001‐1.002], respectively). Conclusions As SUA levels increased, examination fees, cardiovascular disease, pulmonary disease, liver disease, and kidney disease complications increased. SUA level is an independent influence factor for the combination of gout with cardiovascular diseases, pulmonary diseases, liver diseases, and kidney diseases.

show abstract

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review

Cited by 2 publications

References 27 publications

Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions

Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions

Association between serum uric acid levels of patients with gout and their complications and examination fees: A cross‐sectional analysis

Contact Info

Product

Resources

About